In situ osteogenesis: regeneration of 10-cm mandibular defect in porcine model using recombinant human bone morphogenetic protein-2 (rhBMP-2) and Helistat absorbable collagen sponge.
Traditional bone grafting relies upon the incorporation of a bone-cell bearing structure into a recipient site. The graft serves as a scaffold that is eventually replaced and remodeled. This process is known as osteoconduction. Recombinant human bone morphogenetic protein-2 (rhBMP-2) is commercially available as an acellular implant in which the protein is bound to an absorbable collagen sponge (ACS). The rhBMP-2/ACS implant converts undifferentiated mesenchymal stem cells into osteoblasts and promotes an intense local neovascular response. This process, known as osteoinduction, produces bone via membranous, chondroid, or endochondral ossification. The type of bone synthesis depends upon the mesenchymal substrate and the local cellular environment. Using this simple technique, bone defects can be resynthesized with good outcomes and a significant reduction in donor site morbidity. Repair of a critical-sized mandibular resection defect with ISO is described. Basic science concepts of rhBMP-2, relevant histopathologic findings, and clinical application are described.
Carstens
Michael H
MH
Division of Plastic Surgery, Saint Louis University, St. Louis, Missouri 63110, USA. michaelcarstens@mac.com
Chin
Martin
M
Li
X Jian
XJ
D000818:Animals; D001672:Biocompatible Materials / Q000627:therapeutic use*; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000187:drug effects*; D016723:Bone Remodeling / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003094:Collagen / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005781:Gelatin Sponge, Absorbable / Q000627:therapeutic use*; D006801:Humans; D008334:Mandible / Q000473:pathology; D008336:Mandibular Diseases / Q000473:pathology / Q000601:surgery*; D059630:Mesenchymal Stem Cells / Q000187:drug effects; D010006:Osteoblasts / Q000187:drug effects; D010011:Osteocytes / Q000473:pathology; D010012:Osteogenesis / Q000187:drug effects; D019857:Osteogenesis, Distraction / Q000379:methods*; D011994:Recombinant Proteins; D013552:Swine; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*
C525718:BMP2 protein, human; D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D003094:Collagen